top of page

The CEO of Seoul based Bridge Biotherapeutics discusses the importance of drug development experience - a lead program in IPF is scheduled to have a key phase 2 readout next spring

  • blonca9
  • Nov 27, 2024
  • 1 min read

CEO Jame Lee, a founder of multiple biotech companies, describes the operational experience that he suggests is a key differentiator for the company. He then walks us through two lead programs - an autotaxin inhibitor for IPF and a pellino1 inhibitor for inflammatory conditions.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

​

​Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page